Diffusion Tensor Imaging (DTI) analysis was performed in the multi-site
phase II trial of ibudilast in progressive multiple sclerosis. This study
extends that analysis to three pathways to examine DTI measures in 31
progressive MS patients on treatment and 31 patients on placebo. Probabilistic
tracking maps were generated. Mean pathway diffusion measures: longitudinal
diffusivity (LD) and transverse diffusivity (TD) are reported. We report here
that diffusion measures don’t significantly change over time in the treatment
group but we observe a significant change over time in the placebo group.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords